Yasuhiro Fujiwara

6PUBLICATIONS
27CO-AUTHORS
Pharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 04, 2025
Expediting Drug Development in Japan: A PMDA Perspective.

Yoichi Kohno, Akihiro Ishiguro, Takashi Yasukawa

|Aug 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai

|Aug 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Rui Kitadai, Tatsunori Shimoi, Shu Yazaki

|Jan 19, 2023
Challenges in Expediting the Development of Oncology Drugs.

Emi Noguchi, Hiroshi Yaginuma, Yasuhiro Fujiwara

|Oct 17, 2022
High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.

Shu Yazaki, Yuki Kojima, Hiroshi Yoshida

|Sep 21, 2020
Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan.

Seiko Bun, Kan Yonemori, Hiroko Sunadoi

Pageof 1

Frequent Collaborators

5 joint publications

Emi Noguchi

3 joint publications

Kan Yonemori

3 joint publications

Yuki Kojima

2 joint publications

Shu Yazaki